PL2806877T3 - Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny - Google Patents
Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstrynyInfo
- Publication number
- PL2806877T3 PL2806877T3 PL13740743T PL13740743T PL2806877T3 PL 2806877 T3 PL2806877 T3 PL 2806877T3 PL 13740743 T PL13740743 T PL 13740743T PL 13740743 T PL13740743 T PL 13740743T PL 2806877 T3 PL2806877 T3 PL 2806877T3
- Authority
- PL
- Poland
- Prior art keywords
- allopregnanolone
- cyclodextrin
- complex
- sulfobutyl ether
- neuroactive steroid
- Prior art date
Links
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 title 1
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261589740P | 2012-01-23 | 2012-01-23 | |
| EP13740743.3A EP2806877B1 (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| PCT/US2013/022772 WO2013112605A2 (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2806877T3 true PL2806877T3 (pl) | 2020-06-01 |
Family
ID=48874058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13740743T PL2806877T3 (pl) | 2012-01-23 | 2013-01-23 | Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US20150018327A1 (pl) |
| EP (3) | EP2806877B1 (pl) |
| JP (5) | JP2015513316A (pl) |
| CN (2) | CN104736158A (pl) |
| AU (3) | AU2013212287B2 (pl) |
| BR (1) | BR112014018110B1 (pl) |
| CA (1) | CA2862076C (pl) |
| CY (1) | CY1122527T1 (pl) |
| DK (1) | DK2806877T3 (pl) |
| ES (1) | ES2758446T3 (pl) |
| HK (1) | HK1204281A1 (pl) |
| HR (1) | HRP20192348T1 (pl) |
| HU (1) | HUE046800T2 (pl) |
| IL (4) | IL286348B2 (pl) |
| LT (1) | LT2806877T (pl) |
| MX (3) | MX2014008895A (pl) |
| NZ (2) | NZ627781A (pl) |
| PL (1) | PL2806877T3 (pl) |
| PT (1) | PT2806877T (pl) |
| RS (1) | RS59734B1 (pl) |
| RU (2) | RU2681835C2 (pl) |
| SG (2) | SG11201503882SA (pl) |
| SI (1) | SI2806877T1 (pl) |
| WO (1) | WO2013112605A2 (pl) |
| ZA (1) | ZA201405401B (pl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120107533A (ko) | 2005-11-28 | 2012-10-02 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| IL286348B2 (en) | 2012-01-23 | 2023-04-01 | Sage Therapeutics Inc | Pharmaceutical preparations that include allopregnanolone |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| KR102305359B1 (ko) * | 2012-08-21 | 2021-09-24 | 세이지 테라퓨틱스, 인크. | 간질 또는 간질지속 상태를 치료하는 방법 |
| WO2014071449A1 (en) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| CA2892811A1 (en) * | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression |
| NZ769008A (en) | 2014-10-16 | 2024-03-22 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| PT3224269T (pt) | 2014-11-27 | 2020-06-01 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios do snc |
| WO2016164763A1 (en) | 2015-04-10 | 2016-10-13 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| CA2994178C (en) | 2015-08-18 | 2024-03-19 | The Regents Of The University Of California | Nitroxide containing amyloid binding agents for imaging and therapeutic uses |
| US10780099B2 (en) * | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| RU2766155C2 (ru) | 2016-03-08 | 2022-02-08 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, их композиции и применения |
| WO2017160861A1 (en) | 2016-03-15 | 2017-09-21 | The Regents Of The University Of California | Inhibitors for soluble epoxide hydrolase (seh) and fatty acid amide hydrolase (faah) |
| CA3030413A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| EP4406602A2 (en) | 2016-07-11 | 2024-07-31 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US20180050005A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| US20180050107A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108148106A (zh) | 2016-12-05 | 2018-06-12 | 江苏恩华络康药物研发有限公司 | 一类水溶性别孕烯醇酮衍生物及其用途 |
| WO2019075362A1 (en) | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS |
| EA202091144A1 (ru) * | 2017-11-10 | 2020-09-16 | Маринус Фармасьютикалз, Инк. | Ганаксолон для использования в лечении наследственных эпилептических заболеваний |
| WO2020011789A1 (en) | 2018-07-09 | 2020-01-16 | Asarina Pharma Ab | Injectable suspensions |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| CA3136389A1 (en) * | 2019-04-05 | 2020-10-08 | The Regents Of The University Of California | Allopregnanolone compositions and uses thereof |
| JP2022543837A (ja) | 2019-08-05 | 2022-10-14 | マリナス ファーマシューティカルズ， インコーポレイテッド | てんかん重積状態の治療に使用するためのガナキソロン |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN114828889A (zh) | 2019-12-06 | 2022-07-29 | 马瑞纳斯制药公司 | 用于治疗结节性硬化症的加奈索酮 |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸***病症的药物的用途 |
| WO2023028205A1 (en) * | 2021-08-26 | 2023-03-02 | Brandeis University | Selective isonitrile inhibitors of cytochrome p450 subtypes |
| EP4403565A1 (en) | 2021-09-14 | 2024-07-24 | Nanjing Minova Pharmaceutical Co., Ltd. | Water-soluble allopregnanolone derivative, and preparation method therefor and use thereof |
| WO2023240100A1 (en) * | 2022-06-07 | 2023-12-14 | Clarkson Clay Carew | A method to encapsulate non-polar compounds to achieve extended thermal stability and attenuate/prevent thermal and redox isomerization |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (164)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2443266A (en) * | 1944-09-02 | 1948-06-15 | Bendix Aviat Corp | Commutator brush holder |
| US3117142A (en) | 1961-03-01 | 1964-01-07 | Roussel Uclaf | Novel preparation of estradiol and estrone |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3865939A (en) | 1973-02-23 | 1975-02-11 | Procter & Gamble | Edible oils having hypocholesterolemic properties |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| US5847009A (en) | 1986-01-14 | 1998-12-08 | Alliance Pharmaceutical Corp. | Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions |
| SE8600632D0 (sv) | 1986-02-13 | 1986-02-13 | Kabivitrum Ab | Novel pharmaceutical composition |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| EP0603312A4 (en) | 1991-09-13 | 1995-06-07 | Cocensys Inc | NEW GABA A RECEPTOR WITH STEROID BINDING POINTS. |
| US5411737A (en) | 1991-10-15 | 1995-05-02 | Merck & Co., Inc. | Slow release syneresing polymeric drug delivery device |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| DE69518509T2 (de) | 1994-02-14 | 2001-04-19 | Euro-Celtique S.A., Luxemburg/Luxembourg | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| KR20040068613A (ko) | 1994-03-25 | 2004-07-31 | 이소테크니카 인코포레이티드 | 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물 |
| AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| AP653A (en) | 1994-11-23 | 1998-07-21 | Cocensys Inc | Androstane and pregnane series for allosteric modulations of gaba receptor. |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| IL122348A0 (en) | 1995-06-06 | 1998-04-05 | Cocensys Inc | Neuroactive steroids of the androstane and pregnane series |
| WO1997003677A1 (en) | 1995-07-24 | 1997-02-06 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| CA2219698C (en) | 1996-10-31 | 2007-09-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US7630757B2 (en) | 1997-01-06 | 2009-12-08 | Flint Hills Scientific Llc | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US6316613B1 (en) | 1997-07-25 | 2001-11-13 | Beckman Coulter, Inc. | Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis |
| US6245757B1 (en) | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| JP3877961B2 (ja) | 1998-03-11 | 2007-02-07 | ベクストルム，トルビエーン | Ｃｎｓ疾患の治療におけるエピアロプレグナノロン |
| US20020198174A1 (en) | 2001-05-07 | 2002-12-26 | Allergan Sales, Inc. | Disinfecting and solubilizing steroid compositions |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| DE60001623T2 (de) | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| US6442887B2 (en) | 2000-02-25 | 2002-09-03 | Robert L. Sanquist | Live bait keeper |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| WO2002064804A2 (en) | 2001-02-13 | 2002-08-22 | University Of Florida | A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US20030032638A1 (en) | 2001-05-24 | 2003-02-13 | Kim John J. | Delivery of benzodiazepines through an inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| AU2002310085B2 (en) | 2001-05-24 | 2008-09-04 | Alexza Pharmaceuticals, Inc. | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| JP2003063965A (ja) * | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
| EP1465942A4 (en) | 2002-01-14 | 2005-06-29 | Ansell Healthcare Prod Inc | LATEX ARTICLES DETECTABLE THROUGH MAGNETIC |
| US7550155B2 (en) | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| EP2298316A1 (en) | 2002-08-28 | 2011-03-23 | Harbor BioSciences, Inc. | Therapeutic treatment methods |
| US9339508B2 (en) | 2003-01-17 | 2016-05-17 | Mapreg | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury |
| WO2005000869A1 (en) | 2003-05-29 | 2005-01-06 | Washington University | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| US7816074B2 (en) | 2003-07-31 | 2010-10-19 | The Research Foundation Of State University Of New York | α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| AU2004308935A1 (en) * | 2003-12-22 | 2005-07-14 | Schering Corporation | Pharmaceutical compositions |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| DE602005026225D1 (de) | 2004-03-12 | 2011-03-24 | Cipla Ltd | Sterilisationsprozess für Steroide |
| US20090118248A1 (en) | 2004-04-23 | 2009-05-07 | Euro-Celtique S.A. | 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| ITMI20041763A1 (it) | 2004-09-16 | 2004-12-16 | Altergon Sa | Nuove formulazioni iniettabili contenenti progesterone |
| WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US8557861B2 (en) | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| CA2582231A1 (en) | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals, Inc. | Steroid analogs and uses |
| AU2005313975B2 (en) | 2004-12-07 | 2012-09-06 | Onyx Therapeutics, Inc. | Composition for proteasome inhibition |
| US20060198896A1 (en) | 2005-02-15 | 2006-09-07 | Elan Pharma International Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
| EP2494976A1 (en) | 2005-03-24 | 2012-09-05 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
| AU2006235318A1 (en) | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| KR100784860B1 (ko) | 2005-10-31 | 2007-12-14 | 삼성전자주식회사 | 비휘발성 메모리 장치 및 그 제조 방법 |
| KR20120107533A (ko) | 2005-11-28 | 2012-10-02 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| US20070287931A1 (en) | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
| JP2010502722A (ja) | 2006-09-08 | 2010-01-28 | ブレインセルス，インコーポレイティド | ４−アシルアミノピリジン誘導体を含む組み合わせ |
| US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US7813811B2 (en) | 2007-02-08 | 2010-10-12 | Neuropace, Inc. | Refillable reservoir lead systems |
| AU2008240259C1 (en) | 2007-04-11 | 2022-11-24 | Biomarin Pharmaceutical Inc. | Tetrahydrobiopterin compositions and methods of measuring |
| US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
| EP2167098B1 (en) * | 2007-06-11 | 2018-09-05 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function (alzheimer disease) |
| EP2155204B1 (en) | 2007-06-15 | 2016-08-17 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| US20100316678A1 (en) | 2007-06-28 | 2010-12-16 | Cnsbio Pty Ltd. | Combination methods and compositions for treatment of neuropathic pain |
| WO2009082039A1 (en) | 2007-12-26 | 2009-07-02 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ |
| EP2224927B1 (en) | 2008-01-03 | 2014-08-20 | BioMarin Pharmaceutical Inc. | Pterin analog for treating bh4 responsive condition |
| US20090198145A1 (en) | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| US8729070B2 (en) | 2008-02-20 | 2014-05-20 | Targia Pharmaceuticals | CNS pharmaceutical compositions and methods of use |
| DE102008015366A1 (de) | 2008-03-20 | 2009-09-24 | Merck Patent Gmbh | Lyophilisierte Nanoemulsion |
| WO2010063030A2 (en) | 2008-11-30 | 2010-06-03 | Feigelson, Daniel | Dermal application of vasoconstrictors |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| PL3135672T3 (pl) | 2008-10-10 | 2020-11-16 | Vm Discovery, Inc. | Kompozycje i sposoby leczenia zaburzeń używania alkoholu, bólu i innych chorób |
| US20110306579A1 (en) * | 2009-01-30 | 2011-12-15 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| WO2010107922A1 (en) | 2009-03-17 | 2010-09-23 | Duke University | Neuroactive steroid compositions and methods of use for lowering cholesterol |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| RS56576B1 (sr) * | 2010-01-21 | 2018-02-28 | Drawbridge Pharmaceuticals Pty Ltd | Anestetska formulacija |
| RU2576506C2 (ru) | 2010-11-03 | 2016-03-10 | Санофи-Авентис Дойчланд Гмбх | Игольчатая канюля, содержащая лекарственный препарат |
| US20130309306A1 (en) | 2010-12-01 | 2013-11-21 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
| CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| FR2973031B1 (fr) | 2011-03-23 | 2013-11-29 | Univ Strasbourg | Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique |
| US9084797B2 (en) | 2011-05-23 | 2015-07-21 | Besins Healthcare Luxembourg Sarl | Progesterone treatment for improving sleep quality |
| US9526718B2 (en) | 2011-06-28 | 2016-12-27 | Vivozon, Inc. | Combination of effective substances causing synergistic effects of multiple targeting and use thereof |
| CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| CA2848212C (en) | 2011-09-08 | 2022-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| JP2014528485A (ja) | 2011-10-14 | 2014-10-27 | セージ セラピューティクス， インコーポレイテッド | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
| CA2852716C (en) | 2011-11-29 | 2015-11-17 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| WO2013079624A1 (en) | 2011-11-29 | 2013-06-06 | Amino Up Chemical Co., Ltd. | Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function |
| IL286348B2 (en) | 2012-01-23 | 2023-04-01 | Sage Therapeutics Inc | Pharmaceutical preparations that include allopregnanolone |
| WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| KR102305359B1 (ko) * | 2012-08-21 | 2021-09-24 | 세이지 테라퓨틱스, 인크. | 간질 또는 간질지속 상태를 치료하는 방법 |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014071449A1 (en) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| CA2892811A1 (en) | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression |
| JP6542127B2 (ja) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| CN117304245A (zh) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
| CN105339381B (zh) | 2013-04-17 | 2018-04-27 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| IL252848B2 (en) | 2015-02-06 | 2024-07-01 | Marinus Pharmaceuticals Inc | Intravenous Genaxolone Formulations and Their Use in the Treatment of Epileptic Seizures and Other Seizure Disorders |
| GB2541015A (en) | 2015-08-06 | 2017-02-08 | Ge Oil & Gas Uk Ltd | Subsea flying lead |
| AU2016338916B2 (en) | 2015-10-14 | 2021-12-23 | The Regents Of The University Of California | Enhancing beta cell replication and/or survival |
| RU2766155C2 (ru) | 2016-03-08 | 2022-02-08 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, их композиции и применения |
| US20180050005A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| US20180050107A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| KR102630701B1 (ko) | 2016-09-07 | 2024-01-29 | 글리아, 엘엘씨 | 두개 신경의 약리학적 피부 활성화에 의한 신경변성 질환과 관련된 증상의 치료 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| WO2018169798A1 (en) | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
| US20180296487A1 (en) | 2017-04-18 | 2018-10-18 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
| US11752115B2 (en) | 2017-06-21 | 2023-09-12 | The Board Of Trustees Of The University Of Illinois | PPAR-alpha agonist treatment of neuropsychiatric disorders |
| WO2018236955A1 (en) | 2017-06-23 | 2018-12-27 | The Regents Of The University Of California | IMPROVING GABA CAPACITY TO MODULATE IMMUNE RESPONSES |
| WO2018237282A1 (en) | 2017-06-23 | 2018-12-27 | The Board Of Trustees Of The University Of Illinois | TREATMENT OF NEUROPSYCHIATRIC DISORDERS USING NEUROSTEROIDS AND THE LIKE THEREOF |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| EP3681510A1 (en) | 2017-09-14 | 2020-07-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| EA202091144A1 (ru) | 2017-11-10 | 2020-09-16 | Маринус Фармасьютикалз, Инк. | Ганаксолон для использования в лечении наследственных эпилептических заболеваний |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| CN118271387A (zh) | 2017-12-22 | 2024-07-02 | 萨奇治疗股份有限公司 | 治疗cns疾病的组合物和方法 |
| JP2021506904A (ja) | 2017-12-22 | 2021-02-22 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害の処置のための組成物および方法 |
| MA51568A (fr) | 2018-01-12 | 2021-04-21 | Sage Therapeutics Inc | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central |
| US20190337975A1 (en) | 2018-05-04 | 2019-11-07 | Acerus Pharmaceuticals Corporation | Neurosteroid derivatives and uses thereof |
| JP2021527092A (ja) | 2018-06-12 | 2021-10-11 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| ES2966055T3 (es) | 2018-10-12 | 2024-04-18 | Sage Therapeutics Inc | Esteroides neuroactivos sustituidos en la posición 10 con un grupo cíclico para su uso en el tratamiento de trastornos del SNC |
| MX2021004452A (es) | 2018-10-19 | 2021-08-11 | Sage Therapeutics Inc | Esteroides neuroactivos no saturados 9(11) y sus métodos de uso. |
| KR20210112318A (ko) | 2018-12-05 | 2021-09-14 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| JP2022514385A (ja) | 2018-12-21 | 2022-02-10 | セージ セラピューティクス， インコーポレイテッド | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
| TW202110824A (zh) | 2019-05-24 | 2021-03-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| AR119047A1 (es) | 2019-05-31 | 2021-11-17 | Sage Therapeutics Inc | Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc |
| AU2020395246A1 (en) | 2019-12-05 | 2022-06-16 | Sage Therapeutics, Inc. | A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof |
| IL296371A (en) | 2020-03-18 | 2022-11-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸***病症的药物的用途 |
| CN116367827A (zh) | 2020-07-20 | 2023-06-30 | 萨奇治疗股份有限公司 | 19-去甲-c3,3-二取代-c21-n-吡唑基类固醇的制剂及其使用方法 |
-
2013
- 2013-01-23 IL IL286348A patent/IL286348B2/en unknown
- 2013-01-23 RU RU2014134316A patent/RU2681835C2/ru active
- 2013-01-23 JP JP2014553534A patent/JP2015513316A/ja not_active Withdrawn
- 2013-01-23 PL PL13740743T patent/PL2806877T3/pl unknown
- 2013-01-23 CN CN201380015855.5A patent/CN104736158A/zh active Pending
- 2013-01-23 CN CN202011230446.5A patent/CN112472814A/zh active Pending
- 2013-01-23 NZ NZ627781A patent/NZ627781A/en unknown
- 2013-01-23 LT LT13740743T patent/LT2806877T/lt unknown
- 2013-01-23 EP EP13740743.3A patent/EP2806877B1/en active Active
- 2013-01-23 ES ES13740743T patent/ES2758446T3/es active Active
- 2013-01-23 EP EP23192903.5A patent/EP4295908A3/en active Pending
- 2013-01-23 DK DK13740743T patent/DK2806877T3/da active
- 2013-01-23 IL IL298436A patent/IL298436B2/en unknown
- 2013-01-23 PT PT137407433T patent/PT2806877T/pt unknown
- 2013-01-23 AU AU2013212287A patent/AU2013212287B2/en active Active
- 2013-01-23 SI SI201331627T patent/SI2806877T1/sl unknown
- 2013-01-23 RU RU2019104004A patent/RU2019104004A/ru unknown
- 2013-01-23 SG SG11201503882SA patent/SG11201503882SA/en unknown
- 2013-01-23 EP EP19195977.4A patent/EP3650027A1/en not_active Withdrawn
- 2013-01-23 BR BR112014018110-1A patent/BR112014018110B1/pt active IP Right Grant
- 2013-01-23 SG SG10201606063RA patent/SG10201606063RA/en unknown
- 2013-01-23 WO PCT/US2013/022772 patent/WO2013112605A2/en active Application Filing
- 2013-01-23 CA CA2862076A patent/CA2862076C/en active Active
- 2013-01-23 HU HUE13740743A patent/HUE046800T2/hu unknown
- 2013-01-23 MX MX2014008895A patent/MX2014008895A/es active IP Right Grant
- 2013-01-23 RS RS20191698A patent/RS59734B1/sr unknown
- 2013-01-23 US US14/374,080 patent/US20150018327A1/en not_active Abandoned
- 2013-01-23 NZ NZ773177A patent/NZ773177A/en unknown
-
2014
- 2014-07-22 IL IL233744A patent/IL233744B/en active IP Right Grant
- 2014-07-22 ZA ZA2014/05401A patent/ZA201405401B/en unknown
- 2014-07-23 MX MX2022010976A patent/MX2022010976A/es unknown
- 2014-07-23 MX MX2019009739A patent/MX2019009739A/es unknown
-
2015
- 2015-05-21 HK HK15104869.3A patent/HK1204281A1/xx unknown
-
2017
- 2017-07-13 US US15/649,583 patent/US10322139B2/en active Active
- 2017-12-11 JP JP2017236676A patent/JP2018076341A/ja active Pending
-
2018
- 2018-02-22 AU AU2018201307A patent/AU2018201307B2/en active Active
-
2019
- 2019-04-26 US US16/396,065 patent/US11426417B2/en active Active
- 2019-12-12 CY CY20191101309T patent/CY1122527T1/el unknown
- 2019-12-30 HR HRP20192348TT patent/HRP20192348T1/hr unknown
-
2020
- 2020-05-11 JP JP2020082943A patent/JP2020128409A/ja active Pending
- 2020-07-30 IL IL276403A patent/IL276403B/en unknown
- 2020-08-13 AU AU2020217402A patent/AU2020217402B2/en active Active
-
2022
- 2022-04-26 JP JP2022072014A patent/JP7343651B2/ja active Active
- 2022-07-20 US US17/869,145 patent/US20230149424A1/en active Pending
-
2023
- 2023-08-31 JP JP2023140708A patent/JP2023162368A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2806877T3 (pl) | Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny | |
| HRP20181994T1 (hr) | Neuroaktivni steroidi i postupci za njihovu upotrebu | |
| EP2916846A4 (en) | NEUROACTIVE STEROIDS AND THEIR USE TO FACILITATE NEUROPROTECTION | |
| HK1220979A1 (zh) | 刺激神經活性的 -去甲類固醇及其使用方法 | |
| HK1200173A1 (en) | Neuroactive steroids, compositions, and uses thereof | |
| HK1225977B (zh) | 神經活性類固醇、組合物和其用途 | |
| HK1220472A1 (zh) | 神經活性類固醇、組合物、及其用途 | |
| IL225227B (en) | A complex containing cyclodextrin and fulvestrant, its uses and methods for its preparation | |
| EP3021852A4 (en) | Neuroactive steroids, compositions, and uses thereof | |
| GB201008726D0 (en) | Preparation of 12-keto or 12-alpha-hydroxy steroids |